Prosonix inks deal with college to advance inhaled delivery

The U.K.'s Prosonix has an excipient-free platform for inhaled drug delivery, and the company is teaming with Imperial College London to develop treatments for its tech.

Prosonix is hoping to advance its multi-component particles--which combine inhaled treatments into a single, drug-only particle with no excipients--to create therapies for COPD and asthma, the company said, and it's aiming to start preclinical trials by 2013. Prosonix's "smart" combination particles are more effective than standard mixed-powder formulations, according to data the company released in May, and Imperial College London's Omar Usmani said the platform could lead to better treatments for respiratory diseases.

The company recently completed a $27 million fundraising round, and CEO David Hipkiss said partnering with the college is the next step in getting its multi-API formulations into clinics and, eventually, on the market. "We believe that our particle engineering technology is potentially transformational in enabling the development of novel inhaled combination therapies that deliver significant clinical benefits," Hipkiss said in a statement.

Beyond its own pipeline treatments, Prosonix's tech may also boost the effectiveness of existing treatments. The company tested the multi-component platform with a combination of Advair and Symbicort, finding that its formulation maintained the necessary drug ratios and created more effective, efficient and tolerable treatment than standard dry-powder administration.

- read Prosonix's statement
- get more from in-Pharma Technologist